Literature DB >> 2455672

Inhibition of Na+/H+ exchange in the rat is associated with decreased ursodeoxycholate hypercholeresis, decreased secretion of unconjugated urodeoxycholate, and increased ursodeoxycholate glucuronidation.

J R Lake1, E L Renner, B F Scharschmidt, E J Cragoe, L R Hagey, K J Lambert, D Gurantz, A F Hofmann.   

Abstract

In the perfused rat liver, ursodeoxycholate in high dose produces an HCO3- -rich hypercholeresis which we have shown previously to be inhibited by replacement of perfusate Na+ with Li+ or by addition of amiloride (or amiloride analogues). In the present studies, we have determined whether such inhibition is associated with altered ursodeoxycholate biotransformation. Under control conditions, ursodeoxycholate infusion produced a 3.7-fold increase in bile flow and a 9.2-fold increase in biliary HCO3- output. By thin-layer chromatography, ursodeoxycholate radioactivity in bile was present in unconjugated form (15%) or as glycine or taurine amidates. Glucuronide conjugates of ursodeoxycholate accounted for less than 1% of biliary bile acids. Li+/Na+ substitution decreased ursodeoxycholate-stimulated bile flow and HCO3- secretion by greater than 90%, but decreased recovery of ursodeoxycholate and metabolites by only 25%. Amiloride or amiloride analogues decreased ursodeoxycholate-stimulated choleresis and HCO3- output by 38%-76%, yet did not cause decreased recovery of ursodeoxycholate and metabolites. Inhibition of the hypercholeresis was associated with a decrease in unconjugated ursodeoxycholate to less than 2% of total biliary bile acids, a striking increase in ursodeoxycholate glucuronides, and a reciprocal decrease in glycine and taurine amidates. With Li+/Na+ substitution, the predominant metabolites were a mixture of the 24-ester and the 3-aketal (ethereal) glucuronide (29%), and amidation with glycine appeared to be selectively inhibited; with amiloride or its analogues, only the 3-ethereal glucuronide was formed (20%-60% of biliary bile acids), and both taurine and glycine amidation were inhibited. Thus, maneuvers that decrease Na+/H+ exchange inhibit ursodeoxycholate hypercholeresis and cause replacement of unconjugated ursodeoxycholate in bile by its glucuronide. The secretion of unconjugated ursodeoxycholate, a lipophilic bile acid, appears to be necessary for hypercholeresis induced by high-dose ursodeoxycholate infusion.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2455672     DOI: 10.1016/0016-5085(88)90504-5

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  6 in total

1.  Intracellular pH alterations induced by tacrine in a rat liver biliary epithelial cell line.

Authors:  D Lagadic-Gossmann; M Rissel; M Galisteo; A Guillouzo
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

Review 2.  Cellular mechanisms of intrahepatic cholestasis.

Authors:  P J Meier-Abt
Journal:  Drugs       Date:  1990       Impact factor: 9.546

3.  Solvent isotope effect on bile formation in the rat.

Authors:  C Elsing; A Hirlinger; E L Renner; B H Lauterburg; P J Meier; J Reichen
Journal:  Biochem J       Date:  1995-04-01       Impact factor: 3.857

4.  Hypercholeresis with cholate infusion in dogs with pigment gallstones.

Authors:  J Matsumura; K Neri; R V Rege
Journal:  Dig Dis Sci       Date:  1996-02       Impact factor: 3.199

5.  Fecal bile acids, short-chain fatty acids, and bacteria after ileal pouch-anal anastomosis do not differ in patients with pouchitis.

Authors:  W J Sandborn; W J Tremaine; K P Batts; J H Pemberton; S S Rossi; A F Hofmann; G J Gores; S F Phillips
Journal:  Dig Dis Sci       Date:  1995-07       Impact factor: 3.199

6.  Loss of luminal carbonic anhydrase XIV results in decreased biliary bicarbonate output, liver fibrosis, and cholangiocyte proliferation in mice.

Authors:  Zhenzhen Zhou; Jiajie Qian; Archana Kini; Brigitte Riederer; Dorothee Römermann; Gerolf Gros; Ursula Seidler
Journal:  Pflugers Arch       Date:  2022-02-04       Impact factor: 3.657

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.